Teachers Advisors LLC raised its stake in Spark Therapeutics, Inc. (NASDAQ:ONCE) by 1.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,534 shares of the biotechnology company’s stock after buying an additional 650 shares during the period. Teachers Advisors LLC owned about 0.11% of Spark Therapeutics worth $1,842,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of ONCE. Principal Financial Group Inc. raised its position in shares of Spark Therapeutics by 0.3% in the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock valued at $2,067,000 after buying an additional 122 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock valued at $923,000 after buying an additional 414 shares during the last quarter. American International Group Inc. raised its position in shares of Spark Therapeutics by 17.4% in the first quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock valued at $618,000 after buying an additional 1,714 shares during the last quarter. TD Asset Management Inc. raised its position in shares of Spark Therapeutics by 4.5% in the first quarter. TD Asset Management Inc. now owns 76,451 shares of the biotechnology company’s stock valued at $4,078,000 after buying an additional 3,300 shares during the last quarter. Finally, American Century Companies Inc. raised its position in shares of Spark Therapeutics by 0.7% in the first quarter. American Century Companies Inc. now owns 488,519 shares of the biotechnology company’s stock valued at $26,058,000 after buying an additional 3,445 shares during the last quarter. 87.30% of the stock is owned by institutional investors.

Spark Therapeutics, Inc. (ONCE) traded up 1.07% during mid-day trading on Monday, hitting $75.60. The stock had a trading volume of 61,788 shares. Spark Therapeutics, Inc. has a 12 month low of $35.07 and a 12 month high of $80.89. The stock’s market cap is $2.36 billion. The stock’s 50-day moving average price is $69.47 and its 200-day moving average price is $60.53.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter in the prior year, the company posted ($1.04) earnings per share. Spark Therapeutics’s quarterly revenue was up 14.7% compared to the same quarter last year. On average, analysts predict that Spark Therapeutics, Inc. will post ($7.79) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://theolympiareport.com/2017/08/21/spark-therapeutics-inc-once-stake-raised-by-teachers-advisors-llc.html.

Several research analysts have recently commented on the company. Jefferies Group LLC reissued a “buy” rating and set a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Evercore ISI assumed coverage on Spark Therapeutics in a report on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price objective for the company. Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 19th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Wedbush reaffirmed an “underperform” rating and issued a $28.00 target price on shares of Spark Therapeutics in a research note on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus price target of $82.32.

In other Spark Therapeutics news, CFO Stephen W. Webster sold 2,337 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $71.12, for a total value of $166,207.44. Following the completion of the sale, the chief financial officer now directly owns 4,837 shares in the company, valued at approximately $344,007.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Barge Joseph La sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total value of $275,000.00. Following the completion of the sale, the general counsel now owns 9,567 shares of the company’s stock, valued at $526,185. The disclosure for this sale can be found here. Insiders sold a total of 339,310 shares of company stock valued at $23,787,138 over the last quarter. Company insiders own 7.30% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.